Research and development costs climbed to $23.9 million for the quarter, up from $22.3 million a year earlier, driven by rising clinical trial expenses and manufacturing preparations for ozekibart. General and administrative spending also grew to $8.3 million, reflecting pre-commercialization efforts as the company eyes the potential approval of ozekibart in conventional chondrosarcoma. The FDA has set a target date of April 14, 2027, for a decision on that application.
In section Releases
Inhibrx Biosciences Reports Second Quarter Loss Amid Clinical Expansion
Inhibrx Biosciences posted a net loss of $36.7 million for the second quarter of 2026, as the San Diego-based firm increased research spending to advance its oncology pipeline. The company is currently navigating two clinical programs while securing fresh capital to bolster its balance sheet for upcoming regulatory milestones.
To support these operations, Inhibrx finalized a loan amendment with Oxford Finance LLC in July, providing an immediate $100 million cash infusion. This move raised the company's cash position to $219.5 million as of August 6, 2026. Looking ahead, the firm expects to provide key data on its INBRX-106 program in the third quarter of 2026 and plans to discuss accelerated regulatory pathways for its colorectal cancer programs with the FDA later this year.
Comments (0)
No comments yet. Be the first!